Vertex Pharmaceuticals
VRTX
1,438 hedge funds and large institutions have $96.9B invested in Vertex Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 242 funds opening new positions, 559 increasing their positions, 481 reducing their positions, and 60 closing their positions.
303% more first-time investments, than exits
New positions opened: 242 | Existing positions closed: 60
32% more funds holding in top 10
Funds holding in top 10: 31 → 41 (+10)
18% more capital invested
Capital invested by funds: $81.9B → $96.9B (+$15B)
16% more repeat investments, than reductions
Existing positions increased: 559 | Existing positions reduced: 481
13% more funds holding
Funds holding: 1,277 → 1,438 (+161)
1.32% more ownership
Funds ownership: 91.37% → 92.69% (+1.3%)
8% less call options, than puts
Call options by funds: $895M | Put options by funds: $974M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
+$1.41B |
| 2 |
Morgan Stanley
New York
|
+$1.14B |
| 3 |
Amundi
Paris,
France
|
+$286M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
+$252M |
| 5 |
Aberdeen Group
Edinburgh,
United Kingdom
|
+$142M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$510M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$479M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$356M |
| 4 |
BlackRock
New York
|
-$260M |
| 5 |
AllianceBernstein
Nashville,
Tennessee
|
-$180M |
VRTX Hedge Fund Activity: Q4 2023 in Review
1,438 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Vertex Pharmaceuticals (VRTX) for Q4 2023, worth a combined $96.9B — up 18% from $81.9B a quarter earlier.
Buyers outnumbered sellers: 242 funds opened new VRTX positions and 60 closed out — a net gain of 182 holders — while 559 added to existing stakes and 481 trimmed.
The largest buyer was Capital World Investors, adding an estimated $1.41B. The largest seller was Fidelity Investments, cutting an estimated $510M.
- 1,438 institutional investors held Vertex Pharmaceuticals (VRTX) as of Q4 2023, up from 1,277 in Q3 2023.
- Funds reported $96.9B of Vertex Pharmaceuticals stock for Q4 2023, up 18% quarter-over-quarter.
- 242 funds opened new Vertex Pharmaceuticals positions in Q4 2023 and 60 closed out, a net change of +182 holders.
- The largest Vertex Pharmaceuticals buyer in Q4 2023 was Capital World Investors, an estimated $1.41B added.
- The largest Vertex Pharmaceuticals seller in Q4 2023 was Fidelity Investments, an estimated $510M sold.
Based on aggregated 13F filings for Q4 2023.